Connect Biopharma Holdings Limited CNTB PHARMA
Company Overview
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Recent Developments
- Dec 2025 Revenue of $64.00K (-99.8% YoY); net profit $-55.48M.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -19.07% |
| 6 Months: | -27.92% |
| 3 Months: | -13.18% |
| 1 Month: | -13.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.23 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 48.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CNTB Connect Biopharma Holdings Limited PHARMA | 1.91 | -1.61 | $120.28M | 0.00% | -136.77% | -140.51% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 24.12M | 1.22M | 0 | 48.00K | 16.00K | 169.00K |
| Operating Income | -12.63M | 13.65M | -13.85M | -11.45M | -13.42M | -17.68M | -19.61M |
| Net Income | -8.69M | 14.85M | -12.88M | -10.27M | -12.90M | -17.20M | -19.40M |
| Diluted EPS | -0.16 | 0.27 | -0.23 | -0.19 | -0.23 | -0.31 | -0.34 |
| R&D Expense | 8.66M | 5.35M | 9.01M | 6.63M | 8.77M | 11.11M | 15.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 26.03M | 64.00K |
| Operating Income | -69.06M | -22.45M | -58.07M |
| Net Income | -62.11M | -15.63M | -55.48M |
| Diluted EPS | -1.13 | -0.28 | -1.00 |
| R&D Expense | 53.00M | 29.26M | 37.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 127.38M | 101.28M | 56.08M |
| Total Equity | 158.42M | 101.50M | 92.17M | 41.98M |
| Cash & Equivalents | - | 105.66M | 78.23M | 38.34M |
| Total Liabilities | - | 25.88M | 9.12M | 14.10M |
| Current Liabilities | - | 25.29M | 8.46M | 13.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -47.74M | -23.61M | -51.21M |
| Investing Cash Flow | 74.98M | -3.45M | 9.82M |
| Financing Cash Flow | 45.00K | 227.00K | 1.09M |
| Capital Expenditure | -81.00K | -750.00K | -434.00K |
| Free Cash Flow | -47.82M | -24.36M | -51.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | -86.2% | -90,740.6% |
| Net Margin % | - | -60.0% | -86,687.5% |
| ROE % | -61.2% | -17.0% | -132.2% |
| ROCE % | -67.6% | -24.2% | -136.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 7.21% | 4.54M | $5.81M |
| 2 | 683 Capital Management LLC | 2.04% | 1.28M | $1.64M |
| 3 | Boothbay Fund Management, LLC | 1.55% | 973.73K | $1.25M |
| 4 | Blackrock Inc. | 1.38% | 871.65K | $1.12M |
| 5 | Perceptive Advisors Llc | 1.26% | 792.70K | $1.01M |
| 6 | Adar1 Capital Management, LLC | 1.11% | 700.00K | $896.00K |
| 7 | BML Capital Management, LLC | 0.91% | 573.29K | $733.81K |
| 8 | SilverArc Capital Management, LLC | 0.87% | 545.00K | $697.60K |
| 9 | Richmond Brothers, Inc. | 0.85% | 535.61K | $685.58K |
| 10 | Knott David M., Jr. | 0.71% | 444.86K | $569.42K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CNTB
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxNbmtDV2w1aVlIOHF2NW4zbVBaWlhQTy00SHROYmdxYkxrV0hzVHBHdmFPY19CWDF2UkdNX2hLVS1wdGRlOFZQOGpvMk1pUWpsSTg5ZnJZVDNtN1NQdkc1bFc5S3UwVl90R3dkVkNTWUJLLXJYYjdfNW1LTndOOW4yaDlyNktXUzVudmhoS3…
A Sept. 15 live webcast will feature Connect Biopharma management - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNR0Z5LUpqQjh0c0VTSUw1MXY4YVp3YkdlVW9KemJ1OUNuTHJReTRSQW1DUjVFeHoxNk9kNWllRXNBRUREQlB0ajJXQnNaU3FOcXl1NnZPMzFTdnRvdlhkRm41YlRnSGdneEFNRXl1eXpjRHFyS0FlcjFnU3VqOHhmc0VHT3R4cEx6SFhKbk…
$CNTB stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOUkFfRVNMaTFnM1Z1QmRsR0RMS2F6MV9lUmZUWWtsSy1fQU9YRXBWYW5FYjhtdnhVNUI0ZXJJSnhUSk8yU0RqSVROT1NSMnFiU1M3QzBsM3RLcFI1eFQ0MGhScXRQZm5NNFVBMGhyTHE4Rk5MWXdPRkt3cHQwVDRqcjl4dTNicy1ZV25EeX…
CNTB Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5SeWdQcWxqTEJUYmJLZkNaYzJ5RzdsZkc4MmxfcVNyV2ZMNWtGMXV0WS1FR1g5NXk3S1hmWWlIaUN0RHR3ajBrRUFVXzdnejU4VHJBX2Rpc2loeGl5R1pNVTR2MGp5RF82dnh1RE9JSVV2MDFkUTdCNm5B?oc=5" target="_blank">CNT…
CNTB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9mVmdCMHlVb21DSWZYTS1fZzhGQjVzN2ducjBQMFdHdEJrMnNlclc0MDF3YS1wN1RBTTlwYW03REhsS2x6OWc?oc=5" target="_blank">CNTB</a> <font color="#6f6f6f">Finviz</font>…
Connect Biopharma: New Market Opportunity In The Emergency Setting (NASDAQ:CNTB) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRGljTm9IM04zNW9TUEZ1MEhKa2lFNTFJRzNkbmdjcXVxWmxheHdiSDhNaW1pQXgxMTlyT3NUb3R6TV9vbnVUSmVCWDB3NUFnQ0hxMi1DNWJlUVNEb3lWSThiOEpFcWZpWHFRY0pUcW01NVc0QTZfSV8zczBTdFp5b2tCeVhfN0QweTRnbW…
CNTB — Frequently Asked Questions
What is the current share price of Connect Biopharma Holdings Limited (CNTB)?
As of 2026-09-19 21:16 PDT, Connect Biopharma Holdings Limited (CNTB) trades at $1.91 on NasdaqGM. Its 52-week range is $1.32 to $3.69.
What is the market capitalisation of CNTB?
Connect Biopharma Holdings Limited (CNTB) has a market capitalisation of $120.28M on NasdaqGM.
What is the P/E ratio of CNTB?
CNTB trades at a trailing price-to-earnings (P/E) ratio of -1.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.71.
What is the return on equity (ROE) of CNTB?
CNTB has a return on equity (ROE) of -140.51%. Its return on capital employed (ROCE) is -136.77%.
Is CNTB a good stock to buy?
This page provides a data-driven analysis of Connect Biopharma Holdings Limited (CNTB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.